Back to discover
Drug

Isoproterenol

In clinical development
Emerging researchLate-stage development
Also known as (±)-isoprenaline, Duo-Medihaler, Isoprenalina, Isoprenaline+12 more

(±)-isoprenaline, Duo-Medihaler, Isoprenalina, Isoprenaline, Isoprenalinum, Isopropyl noradrenaline, Isoprénaline, Isuprel, Medihaler-Iso, N-Isopropylnoradrenaline, N-Isopropylnorepinephrine, (±)-isoproterenol, 1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanol, 1-(3,4-dihydroxyphenyl)-2-isopropylaminoethanol, Isoproterenol Hydrochloride, Isoproterenol Sulfate.

1
Research papers
5
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Exercise-induced Adrenergic Receptor Signaling as an Immune Adjuvant for Allogeneic Cell Therapies

Clinical trial2026-06-05Results expected Q2 2031 · ClinicalTrials.gov

Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences

Clinical trial2026-01-08Results expected Q4 2027 · ClinicalTrials.gov

Early Neurovascular Adaptations in Aging Women

Clinical trial2025-11-26Results expected Q2 2027 · ClinicalTrials.gov

Autoimmune Basis for Postural Tachycardia Syndrome

Clinical trial2025-11-12Results expected Q4 2026 · ClinicalTrials.gov

Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa

Clinical trial2023-06-01Completed · ClinicalTrials.gov

Augmented Interoceptive Exposure Training for the Fear of Food in Anorexia Nervosa

Clinical trial2021-08-01Primary completion · ClinicalTrials.gov

Decision Support for Intraoperative Low Blood Pressure

Clinical trial2019-05-16Results posted · ClinicalTrials.gov

Adenosine Study in Paroxysmal Atrial Fibrillation

Clinical trial2017-12-13Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Isoproterenol
Aliases & brands
(±)-isoprenalineDuo-MedihalerIsoprenalinaIsoprenalineIsoprenalinumIsopropyl noradrenalineIsoprénalineIsuprelMedihaler-IsoN-IsopropylnoradrenalineN-Isopropylnorepinephrine(±)-isoproterenol1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanol1-(3,4-dihydroxyphenyl)-2-isopropylaminoethanolIsoproterenol HydrochlorideIsoproterenol Sulfate
RxNorm CUI
6054
ChEMBL ID
CHEMBL434
ATC codes
C01CA02R03CB51R03AB02R03CB01
UNII
L628TT009W

Clinical trials

14 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
14
registered trials across all phases
LATEST COMPLETION 2023
5
Active studies
5
Recruiting
9
Late-stage (III+)
7
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 14
Early Phase 13Phase 22Phase 2 / 31Phase 41Phase N / A7

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes1
Interoception1
Journals, researchers & institutions
Top journals
  • eLife1
Leading researchers
  • Adamic EM1
  • Avery J1
  • de la Cruz F1
  • Khalsa S1
  • Teed AR1
Leading institutions
free-text, unnormalised
  • Laboratory for Autonomic Neuroscience1
  • Laboratory of Brain and Cognition1
  • Laureate Institute for Brain Research1
  • Semel Institute for Neuroscience and Human Behavior1
  • University of Tulsa1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials